The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Open accessAbstract
Mutationally activated kinases define a clinically validated class of targets for cancer drug therapy. However, the efficacy of kinase inhibitors in patients whose tumours harbour such alleles is invariably limited by innate or acquired drug resistance. The identification of resistance mechanisms has revealed a recurrent theme—the engagement of survival signals redundant to those transduced by the targeted kinase. Cancer cells typically express multiple receptor tyrosine kinases (RTKs) that mediate signals that converge on common critical downstream cell-survival effectors—most notably, phosphatidylinositol-3-OH kinase (PI(3)K) and mitogen-activated protein kinase (MAPK). Consequently, an increase in RTK-ligand levels, through autocrine tumour-cell production, paracrine contribution from tumour stroma or systemic production, could confer resistance to inhibitors of an oncogenic kinase with a similar signalling output. Here, using a panel of kinase-'addicted' human cancer cell lines, we found that most cells can be rescued from drug sensitivity by simply exposing them to one or more RTK ligands. Among the findings with clinical implications was the observation that hepatocyte growth factor (HGF) confers resistance to the BRAF inhibitor PLX4032 (vemurafenib) in BRAF-mutant melanoma cells. These observations highlight the extensive redundancy of RTK-transduced signalling in cancer cells and the potentially broad role of widely expressed RTK ligands in innate and acquired resistance to drugs targeting oncogenic kinases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example HGF has been found to confer resistance to the BRAF inhibitor vemurafenib in BRAF-mutant melanoma cells (Wilson et al., 2012).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Wilson et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Friends or foes — bipolar effects of the tumour stroma in cancer
Mueller, M. M., & Fusenig, N. E. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1477 · Cited by 1,817
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
Self-citationCOT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,000
The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma
Amaral, T. M. S., Nouri, N., & Garbe, C. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1192469 · Cited by 13
Trans-activating mutations of the pseudokinase ERBB3
Koivu, M. K. A., Chakroborty, D., Airenne, T. T., Johnson, M. S., Kurppa, K. J., & Elenius, K. (2024) · Oncogene · doi:10.1038/s41388-024-03070-9 · Cited by 12
Pan, B., Wang, R., Zhang, J., Chen, H., Huang, Y., & Garfield, D. H. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s78116 · Cited by 12
Targeted Therapies for Cutaneous Melanoma
Kee, D., & McArthur, G. A. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.02.003 · Cited by 12
Pertuzumab Protects the Achilles' Heel of Trastuzumab—Emtansine
Gwin, W. R., & Spector, N. L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2626 · Cited by 12
Controversies in the Management of Advanced Melanoma
Jarkowski, A., Norris, L. B., & Trinh, V. A. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014544165 · Cited by 12
Krisp, C., Parker, R., Pascovici, D., Hayward, N. K., Wilmott, J. S., Thompson, J. F., Mann, G. J., Long, G. V., Scolyer, R. A., & Molloy, M. P. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0227-2 · Cited by 11
Cholesterol Regulates the Tumor Adaptive Resistance to MAPK Pathway Inhibition
Wang, X., Kim, C., Zhang, Y., Rindhe, S., Cobb, M. H., & Yu, Y. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00550 · Cited by 14
The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy
Akabane, H., & Sullivan, R. J. (2015) · American Journal of Clinical Dermatology · doi:10.1007/s40257-015-0159-z · Cited by 12
Creating Chemotherapeutic-Resistant Breast Cancer Cell Lines: Advances and Future Perspectives
Steding, C. E. (2016) · Future Oncology · doi:10.2217/fon-2016-0059 · Cited by 13
The complexity of microenvironment-mediated drug resistance
Smalley, I., & Smalley, K. S. M. (2015) · Genes & Cancer · doi:10.18632/genesandcancer.82 · Cited by 12
The HGF-cMET signaling pathway in conferring stromal-induced BRAF-inhibitor resistance in melanoma
Filitis, D. C., Rauh, J., & Mahalingam, M. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000194 · Cited by 11
Mitochondrial-Targeting MET Kinase Inhibitor Kills Erlotinib-Resistant Lung Cancer Cells
Yang, T., Ng, W. H., Chen, H., Chomchopbun, K., Huynh, T. H., Go, M., & Kon, O. L. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00223 · Cited by 12
Non-autonomous cell proliferation in the mammary gland and cancer
Weber, R. J., Desai, T. A., & Gartner, Z. J. (2017) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2017.02.009 · Cited by 12
The great escape: How metastases of melanoma, and other carcinomas, avoid elimination
Wells, A. H., Clark, A. M., Bradshaw, A. M., Ma, B., & Edington, H. J. D. (2018) · Experimental Biology and Medicine · doi:10.1177/1535370218820287 · Cited by 12
de Moura, C. R., Prunotto, M., Sohail, A., Battistella, M., Jouenne, F., Marbach, D., Lebbé, C., Fridman, R., & Mourah, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01748 · Cited by 12
Rabia, E., Garambois, V., Hubert, J., Bruciamacchie, M., Pirot, N., Delpech, H., Broyon, M., Theillet, C. G., Colombo, P., Vié, N., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1914883 · Cited by 12
Molecular Pathways: Comparing the Effects of Drugs and T Cells to Effectively Target Oncogenes
Anders, K., & Blankenstein, T. J. F. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3017 · Cited by 12
Wang, V. E., Blaser, B. W., Patel, R. K., Behbehani, G. K., Rao, A. A., Durbin-Johnson, B., Jiang, T., Logan, A. C., Settles, M., Mannis, G. N., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0055 · Cited by 11
Sex-Based Differences in the Tumor Microenvironment
Wuidar, V., Gillot, L., Silva, I. D. D., Lebeau, A., Gallez, A., & Péqueux, C. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-73119-9_23 · Cited by 11
Levati, L., Tabolacci, C., Facchiano, A., Facchiano, F., Alvino, E., Cappellini, G. C. A., Scala, E., Bonmassar, L., Caporali, S., Lacal, P. M., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03151-3 · Cited by 12
Kučerová, L., Demková, L., Miklikova, S., Bohovic, R., & Matúšková, M. (2016) · BMC Cancer · doi:10.1186/s12885-016-2341-y · Cited by 11
Kamashev, D., Shaban, N., Suntsova, M., Raevskiy, M., Efimov, V., Moisseev, A., Sorokin, M., & Buzdin, A. A. (2022) · Biomedicines · doi:10.3390/biomedicines10081914 · Cited by 12
Prognostic and Predictive Significance of Stromal Fibroblasts and Macrophages in Colon Cancer
Owusu, B. Y., Vaid, M., Kaler, P., & Klampfer, L. (2015) · Biomarkers in Cancer · doi:10.4137/bic.s25247 · Cited by 11
Claas, A., Atta, L., Gordonov, S., Meyer, A. S., & Lauffenburger, D. A. (2018) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-018-0542-y · Cited by 11
Herrmann, M. D., Lennerz, J. K., Bullinger, L., Bartholomae, S., Holzmann, K., Westhoff, M., Corbacioglu, S., & Debatin, K. (2013) · Experimental Hematology · doi:10.1016/j.exphem.2013.10.006 · Cited by 11
The impact of tumor stromal architecture on therapy response and clinical progressionPreprint
Altrock, P. M., Yoon, N., Bull, J. A., Wu, H., Ruiz-Ramírez, J., Miroshnychenko, D., Kimmel, G. J., Kim, E., Velde, R. V., Rejniak, K. A., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/451047 · Cited by 11
Huwaimel, B., Abouzied, A. S., Zaki, M. E. A., Alamri, A., Farag, B., Alqarni, S., & Gomha, S. M. (2025) · ChemistryOpen · doi:10.1002/open.202500288 · Cited by 10
Treatment of BRAF-mutated advanced cutaneous melanoma.
Trinh, V. A., You, Y., & Hwu, W. (2014) · PubMed · doi:10.3978/j.issn.2304-3865.2014.05.10 · Cited by 10
Wolnicka-Głubisz, A., Strickland, F. M., Wielgus, A. R., Anver, M. R., Merlino, G. T., Fabo, E. C. D., & Noonan, F. P. (2014) · International Journal of Cancer · doi:10.1002/ijc.29050 · Cited by 10
Melnick, M., Deluca, K. A., Sedghizadeh, P. P., & Jaskoll, T. F. (2013) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2013.01.005 · Cited by 10
Protein kinase inhibitors in melanoma
Eigentler, T., Meier, F., & Garbe, C. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.827172 · Cited by 9
Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions
Moasser, M. M. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1121 · Cited by 9
Melnick, M., Sedghizadeh, P. P., Deluca, K. A., & Jaskoll, T. F. (2013) · Herpesviridae · doi:10.1186/2042-4280-4-1 · Cited by 10
New treatments for metastatic melanoma
Gedye, C. A., Hogg, D., Butler, M. O., & Joshua, A. M. (2014) · Canadian Medical Association Journal · doi:10.1503/cmaj.130989 · Cited by 10
Zaleśna, I., Osrodek, M., Hartman, M. L., Różański, M., Sztiller-Sikorska, M., Niewinna, K., Nejc, D., & Czyż, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183498 · Cited by 10
Yin, Y., Zhou, Y., Sha, S., Wu, X., Wang, S., Qiao, F., Song, Z., & Zhu, H. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103238 · Cited by 10
DiCara, D. M., Chirgadze, D. Y., Pope, A. R., Karatt-Vellatt, A., Winter, A., Slavny, P., van den Heuvel, J., Parthiban, K., Holland, J. D., Packman, L. C., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09460-2 · Cited by 10
Mou, Y., Huang, J., Yang, W., Wan, Y., Pu, Z., Zhang, J., Liu, J., Li, Q., Zhang, P., Tian, Y., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1023391 · Cited by 9
Xu, C., Lv, P.-H., Huang, X., Wang, S., Sun, L., & Wang, F. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.14.6159 · Cited by 9
Yan, L., Zhang, L., Zhang, Y., Qiao, X., Pan, J., Liu, H., Lü, S., Xiang, B., Lu, T., & Yuan, H. (2017) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2017.1340852 · Cited by 9
Ahn, S. W., Ferland, B., & Jonas, O. H. (2021) · Journal of Pathology Informatics · doi:10.4103/jpi.jpi_17_21 · Cited by 9
Development of resistance to FGFR inhibition in urothelial carcinoma via multiple pathways in vitro
Pettitt, G. A., Hurst, C. D., Khan, Z., McPherson, H. R., Dunning, M. C., Alder, O., Platt, F. M., Black, E. V. I., Burns, J. E., & Knowles, M. A. (2022) · The Journal of Pathology · doi:10.1002/path.6034 · Cited by 10
Early Combined SHP2 Targeting Reverses the Therapeutic Resistance of Vemurafenib in Thyroid Cancer
Ma, W., Tian, M., Hu, L., Ruan, X., Zhang, W., Zheng, X., & Gao, M. (2023) · Journal of Cancer · doi:10.7150/jca.83853 · Cited by 11
Liu, H., Ruan, S., Larsen, M. E., Tan, C., Liu, B., & Lyu, H. (2023) · Biological Procedures Online · doi:10.1186/s12575-023-00212-3 · Cited by 9
Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
Yarar, D., Lahdenranta, J., Kubasek, W., Nielsen, U. B., & MacBeath, G. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0075 · Cited by 9
Microenvironmental InterFereNce of metabolism regulates chemosensitivity
Akkari, L., & Joyce, J. A. (2016) · Cell Research · doi:10.1038/cr.2016.82 · Cited by 9
Inhibition du récepteur MET : un espoir dans la lutte contre les résistances aux thérapies ciblées ?
Hochart, A., Leblond, P., Bourhis, X. L., Meignan, S., & Tulasne, D. (2016) · Bulletin du Cancer · doi:10.1016/j.bulcan.2016.10.014 · Cited by 9
Liu, R., Tang, W., Han, X., Geng, R., Wang, C., & Zhang, Z. (2018) · Oncology Letters · doi:10.3892/ol.2018.9414 · Cited by 9
McGee, S. F., Kornblau, S. M., Qiu, Y., Look, A. T., Zhang, N., Yoo, S.-Y., Coombes, K. R., & Kentsis, A. (2014) · Leukemia · doi:10.1038/leu.2014.348 · Cited by 9
Wang, Y., Zhan, Z., Jiang, X., Xia, P., Shen, Y., Chen, F., Ji, Y., Liu, W., Shi, Y., Duan, W., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9349 · Cited by 9
The PI3K-AKT Pathway in Melanoma
Siroy, A. E., Davies, M. A., & Lazar, A. J. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3554-3_7 · Cited by 8
Chai, C.-S., Liam, C. K., Poh, M. E., Ong, D. B., Pang, Y., Cheah, P., Ho, G. F., & Alip, A. (2020) · Cancer Management and Research · doi:10.2147/cmar.s253760 · Cited by 8
McClure, E., Carr, M. J., & Zager, J. S. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1796646 · Cited by 9
Kobayashi, P. E., Lainetti, P. D. F., Leis‐Filho, A. F., Delella, F. K., de Carvalho, M., Cury, S. S., Carvalho, R. F., Fonseca‐Alves, C. E., & Amorim, R. L. (2020) · Frontiers in Veterinary Science · doi:10.3389/fvets.2020.561212 · Cited by 9
Buccinnà, B., Ramondetti, C., & Piccinini, M. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115228 · Cited by 8
MAPK-negative feedback regulation confers dependence to JAK2V617F signaling
Kesarwani, M., Kincaid, Z., Azhar, M., Menke, J., Schwieterman, J., Ansari, S., Reaves, A., Deininger, M. W., Levine, R. L., Grimes, H. L., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01959-0 · Cited by 10
Hematopoietic Stem Cells and Their Bone Marrow Niches
Pinho, S., & Zhao, M. L. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-99-7471-9_2 · Cited by 9
Tozuka, T., Noro, R., Yoshida, K., Takahashi, S., Hirao, M., Matsuda, K., Kato, Y. X., Nakamichi, S., Takeuchi, S., Matsumoto, M., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100668 · Cited by 11
Zanrè, V., Bellinato, F., Cardile, A., Passarini, C., Bella, S. D., & Menegazzi, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211939 · Cited by 9
Zha, Z., Liu, C., Yan, M., Chen, C., Cheng, Y., Chen, Y., Zhou, C., Li, L., Li, Y., Yamaguchi, H., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02206-x · Cited by 9
Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor
Desole, C., Gallo, S., Vitacolonna, A., Vigna, E., Basilico, C., Montarolo, F., Zuppini, F., Casanova, E., Miggiano, R., Ferraris, D. M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.775151 · Cited by 8
Kokabee, M., WANG, X., Voorand, E., Alin, E., Kokabee, L., Khan, F., DESROSIERS, S., & Conklin, D. S. (2022) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20329 · Cited by 8
Wang, X., Li, W., Yin, Y., Tong, Z., Zhang, Q., Zheng, H. Y., Shao, Z., Li, H., Yang, J., Feng, J., et al. (2023) · Translational Breast Cancer Research · doi:10.21037/tbcr-23-2 · Cited by 8
RTK Inhibition: Looking for the Right Pathways Toward a Miracle
Xie, Q. R., Woude, G. F. V., & Berens, M. E. (2012) · Future Oncology · doi:10.2217/fon.12.130 · Cited by 8
Radiofrequency Ablation in Treating Colorectal Cancer Patients with Liver Metastases
Xu, C., Huang, X., Lv, P.-H., Wang, S., Sun, L., & Wang, F. (2016) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.18.8559 · Cited by 8
van den Heuvel, C. N. A. M., Navis, A. C., de Bitter, T. J. J., Amiri, H., Verrijp, K. N., Heerschap, A., Rex, K. L., Dussault, I., Caenepeel, S. R., Coxon, A., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0177 · Cited by 7
Lee, I., Yang, J., Hsieh, M., Huang, C., Huang, H., Ku, Y., Wu, Y., Huang, K.-C., & Chen, J. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01598-5 · Cited by 8
Yang, K.-S., Che, P.-C., Hsieh, M., Lee, I., Wu, Y., Chen, M., & Chen, J. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12552 · Cited by 8
Wang, Y., Zhang, Y., Chen, R., & Tian, X. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1047 · Cited by 8
Ahn, J., & Lee, M. (2014) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-014-2034-2 · Cited by 8
Microfluidic devices, accumulation of endogenous signals and stem cell fate selection
Fattahi, P., Haque, A., Son, K. J., Guild, J., & Revzin, A. (2019) · Differentiation · doi:10.1016/j.diff.2019.10.005 · Cited by 8
Miti, T., Desai, B., Miroshnychenko, D., Basanta, D., & Marusyk, A. (2024) · Cancers · doi:10.3390/cancers16132405 · Cited by 7
Covalent inhibitor design confers activity against both GDP- and GTP-bound forms of KRAS G12C
Condakes, M. L., Zhang, Z., Danahy, D. B., Moore, R. R., Lakkaraju, S. K., Zhuo, X., Amako, Y., Borzilleri, R. M., Balachander, S. B., Chourb, L. S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69003-0 · Cited by 8
Reang, J., Sharma, V., Yadav, V., Tonk, R. K., Majeed, J., Sharma, A. K., & Sharma, P. C. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03252-w · Cited by 8
An In Vivo Inflammatory Loop Potentiates KRAS Blockade
Arendt, K. A. M., Ntaliarda, G., Armenis, V., Kati, D., Henning, C., Giotopoulou, G. A., Pepe, M. A. A., Klotz, L. V., Lamort, A., Hatz, R. A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10030592 · Cited by 7
Tsukamoto, Y., Hirashita, Y., Shibata, T., Fumoto, S., Kurogi, S., Nakada, C., Kinoshita, K., Fuchino, T., Murakami, K., Inomata, M., et al. (2023) · Cancers · doi:10.3390/cancers15164104 · Cited by 8
Hall, P. E., Spicer, J. F., & Popat, S. (2015) · Future Oncology · doi:10.2217/fon.15.110 · Cited by 7
Zomerman, W. W., Plasschaert, S. L. A., Diks, S. H., Lourens, H.-J., Boer, T. M.-D., Hoving, E. W., den Dunnen, W. F. A., & de Bont, E. S. J. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141381 · Cited by 7
Kamata, T., Dankort, D. L., Kang, J., Giblett, S. M., Pritchard, C. A., McMahon, M., & Leavitt, A. D. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0294 · Cited by 7
ETS1 inactivation causes innate drug resistance to EGFR inhibitors
Tetsu, O., Phuchareon, J., Eisele, D. W., & McCormick, F. P. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1078924 · Cited by 7
Promise and challenges on the horizon of MET-targeted cancer therapeutics
Zhang, Y.-W. (2015) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v6.i2.16 · Cited by 7
Puszkiel, A., White‐Koning, M., Dupin, N., Kramkimel, N., Thomas‐Schoemann, A., Noé, G., Chapuis, N., Vidal, M., Goldwasser, F., Chatelut, É., et al. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.06.032 · Cited by 7
Wang, E. A., Chen, W.-Y., & Wong, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-59466-6 · Cited by 10
Kamynina, М., Rozenberg, J. M., Kushchenko, A. S., Dmitriev, S. E., Modestov, A., Kamashev, D., Гайфуллин, Н., Shaban, N., Suntsova, M., Emelianova, A. A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212049 · Cited by 6
Chen, C., Wang, S., Yang, J.-M., & Huang, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073040 · Cited by 8
A comprehensive review of targeting RAF kinase in cancer
Hossain, M. A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177142 · Cited by 6
The ErbB3-binding protein EBP1 modulates lapatinib sensitivity in prostate cancer cells
Awasthi, S., Ezelle, H. J., Hassel, B. A., & Hamburger, A. W. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2409-z · Cited by 6
Walker, M. J. (2017) · Medicine Health Care and Philosophy · doi:10.1007/s11019-017-9807-9 · Cited by 6
Antibody drug conjugates for patients with breast cancer
Medford, A. J., Spring, L. M., Moy, B., & Bardia, A. (2021) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2021.100795 · Cited by 6
Small molecule induces mitochondrial impairment in colon cancer cells
Shinde, S., Chhabria, D., Ingle, J., Kumar, M., Kirubakaran, S., & Basu, S. (2022) · New Journal of Chemistry · doi:10.1039/d2nj03242b · Cited by 6
Buchbinder, E. I., Giobbie‐Hurder, A., & Ott, P. A. (2023) · Investigational New Drugs · doi:10.1007/s10637-023-01364-5 · Cited by 6
Hepatocyte growth factor—a culprit of drug resistance
Razzak, M. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.124 · Cited by 6
BST-2: at the Crossroads of Viral Pathogenesis and Oncogenesis
Mahauad‐Fernandez, W. D., & Okeoma, C. M. (2016) · Future Virology · doi:10.2217/fvl.15.113 · Cited by 6
Haley, J. D., & White, F. M. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140038 · Cited by 6
Zhang, H., Wang, L., Ai, J., Chen, Y., He, C.-X., Ji, Y., Huang, M., Yang, J., Zhang, A., Ding, J., et al. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.214817 · Cited by 6
Trametinib for patients with advanced melanoma
Masuda, S., & Belmonte, J. C. I. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70419-9 · Cited by 6
Kirouac, D., Lahdenranta, J., Du, J., Yarar, D., Onsum, M., Nielsen, U., & McDonagh, C. (2015) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.19 · Cited by 5
George, N., Bajaj, S., Sabahi, B. A., Akhtar, M. J., & Khan, S. A. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11127-5 · Cited by 5
Tejpar, S., & Piessevaux, H. H. (2014) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12176 · Cited by 5
Metadata
- Authors
- Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., Ribas, A., Li, J., Moffat, J., Sutherlin, D. P., Koeppen, H., Merchant, M., Neve, R., & Settleman, J.
- Affiliations
- Genentech (US)
- Vanderbilt University Medical Center (US)
- University of California, Los Angeles (US)
- Corresponding author
- Settleman, Jeff
- ORCID
- Venue
- Nature
- Published
- 2012-07
- Volume
- 487
- Issue
- 7408
- Pages
- 505-509
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3724525
- OpenAlex
- W1999025555
- Cited by
- 1,134
- References
- 29
- Citations by year
- 2026: 23 · 2025: 16 · 2024: 31 · 2023: 46 · 2022: 47 · 2021: 51 · 2020: 65 · 2019: 70 · 2018: 85 · 2017: 87 · 2016: 125 · 2015: 137 · 2014: 166 · 2013: 150 · 2012: 34
- FWCI
- 62.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (K24CA097588)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- drug resistance, kinase inhibitors, receptor tyrosine kinase, growth factors, hepatocyte growth factor, BRAF inhibitors, vemurafenib, melanoma, tumor microenvironment, phosphatidylinositol 3-kinase, mitogen-activated protein kinase, combination therapy
- MeSH terms
- Lapatinib, Vemurafenib, Antineoplastic Agents, Breast Neoplasms, Cell Survival, Female, Humans, Indoles, Ligands, Melanoma, Quinazolines, Sulfonamides, Signal Transduction, Hepatocyte Growth Factor, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Receptor Protein-Tyrosine Kinases, Mitogen-Activated Protein Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
